1.
A guide to immunotherapy for COVID-19
by van de Veerdonk, Frank L
Nature medicine, 2022, Vol.28 (1), p.39-50
2.
Preventive therapy for breast cancer: a consensus statement
by Cuzick, Jack, Prof
The lancet oncology, 2011, Vol.12 (5), p.496-503
3.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
4.
Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
by Razonable, Raymund R., MD
Mayo Clinic proceedings, 2011, Vol.86 (10), p.1009-1026
5.
Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?
by Huber, Kurt, MD
The American heart journal, 2014, Vol.168 (5), p.611-621
6.
Up-to-date approach to manage keloids and hypertrophic scars: A useful guide
by Arno, Anna I
Burns, 2014, Vol.40 (7), p.1255-1266
7.
Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary...
by Hansmann, Georg
Heart (British Cardiac Society), 2016, Vol.102 (Suppl 2), p.ii67-ii85
8.
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature
by Bajwah, Sabrina
Thorax, 2013, Vol.68 (9), p.867-879
9.
Guidelines for the management of inflammatory bowel disease in adults
by Mowat, Craig
Gut, 2011, Vol.60 (5), p.571-607
10.
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures
by Levy, Jerrold H., MD
The American journal of emergency medicine, 2016, Vol.34 (11), p.14-18
11.
Malaria
by White, Nicholas J, Prof
The Lancet (British edition), 2014, Vol.383 (9918), p.723-735
12.
Antiangiogenic therapy in oncology: current status and future directions
by Jayson, Gordon C, Prof
The Lancet (British edition), 2016, Vol.388 (10043), p.518-529
13.
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT...
by Perez-Molina, José A, PhD
The Lancet infectious diseases, 2015, Vol.15 (7), p.775-784
14.
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
by Zhao, Xiaoxuan
European journal of clinical microbiology & infectious diseases, 2020, Vol.39 (7), p.1209-1220
15.
A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
by Appleby, Brian S
Dementia and geriatric cognitive disorders, 2013, Vol.35 (1-2), p.1-22
16.
Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update
by Dworkin, Robert H., PhD
Mayo Clinic proceedings, 2010, Vol.85 (3), p.S3-S14
17.
Lipid-Modifying Effects of Nutraceuticals: An Evidence-Based Approach
by Sahebkar, Amirhossein
Nutrition (Burbank, Los Angeles County, Calif.), 2016, Vol.32 (11-12), p.1179-1192
18.
Risk Factors for the Development of Delayed TSH Elevation in Neonatal Intensive Care Unit Newborns
by Zung, Amnon
The journal of clinical endocrinology and metabolism, 2017, Vol.102 (8), p.3050-3055
19.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
by Boeree, Martin J, PhD
The Lancet infectious diseases, 2016, Vol.17 (1), p.39-49
20.
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical...
by Backus, L. I.
Alimentary pharmacology & therapeutics, 2016, Vol.44 (4), p.400-410
